Vitamin D Testing
Customize your policy alerts
Sign up for all Oscar Health policy alerts
Know when Oscar Health releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity, coverage limitations, and testing methods for serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D testing for Oscar Health members.
No material clinical or coverage changes in this revision.
Coverage Criteria
25-hydroxyvitamin D (25OHD) testing
Covered when ALL of the following are met for 25-hydroxyvitamin D testing:
See Note 1 for covered indications list.
D2 and D3 fraction testing
Covered when performed as part of total 25-hydroxyvitamin D analysis:
1,25-dihydroxyvitamin D testing
Covered when ALL of the following are met for 1,25-dihydroxyvitamin D testing:
See Note 2 for indications list.
Not medically necessary / Not covered
These testing indications do not meet criteria.
Medically necessary/appropriate testing scenarios
Covered when testing is for clinically justified indications or monitoring in at‑risk patients. Examples include:
supported by clinical conditions list
guideline support in chunks 34 and 30
see therapeutic criteria
society recommendation (chunks 33)
NHS, RACGP, Manchester guidance (chunk 36)
Repeat testing guidance
Repeat vitamin D measurement is generally not recommended except in specific clinical situations.
Repeat testing should not be done within three months of the initial test, and preferably not within six months.
Testing vs empiric treatment for asymptomatic high-risk individuals
Recommendation from referenced trust regarding high-demand testing reduction.
Guidance aims to reduce unnecessary testing workload.
Routine screening for vitamin D deficiency with serum testing in asymptomatic individuals or during general encounters is excluded from coverage. Measurement of serum 25-hydroxyvitamin D for the purpose of population-level or opportunistic screening does not meet criteria in the absence of a documented clinical indication.
Routine population screening of asymptomatic individuals is not supported. Major guideline panels—including The Endocrine Society, the USPSTF, and the American Academy of Pediatrics—recommend against routine 25(OH)D screening in the general adult population (including different adult age groups), during pregnancy, and in otherwise healthy children without conditions affecting bone health. Screening of these populations is therefore excluded unless a specific clinical indication is documented.
Repeat vitamin D testing is excluded for the majority of patients and should be avoided without clinical justification. Per the cited guidance, repeat measurement should not be performed within three months of an initial test and is preferably deferred until at least six months in most patients unless one of the specified clinical indications for retesting applies.
Measurement of serum 1,25-dihydroxyvitamin D for the purpose of screening for vitamin D deficiency is not medically necessary and does not meet coverage criteria. 1,25-dihydroxyvitamin D testing is reserved for evaluation of specific disorders of vitamin D metabolism rather than routine status assessment.
Routine measurement of serum 25-hydroxyvitamin D (25[OH]D) for screening in the general population is not supported by the evidence and is excluded. Multiple guideline sources conclude there is insufficient evidence of benefit for population-based screening (including adults across age groups, pregnant individuals, and healthy children), so routine 25(OH)D testing in asymptomatic persons is not covered absent an accepted clinical indication.
Routine repeat measurement of 25(OH)D is generally not recommended. Repeat testing may be considered only for narrowly defined clinical scenarios (for example, symptomatic deficiency, malabsorption on replacement therapy, or patients on anti-resorptive therapy with low baseline levels). When repeat testing is indicated, it should not be done within three months of initiating therapy and is preferably deferred until at least six months in most patients.
Indications for Testing (Covered)
List of specific disorders/conditions where serum 25OHD or 1,25-dihydroxyvitamin D testing is indicated (see Note 1 and Note 2)
See Note 1 and Note 2 for specific listed disorders/conditions where serum 25OHD or 1,25-dihydroxyvitamin D testing is indicated:
Derived from Note 1 (chunk 5)
Derived from Note 2 (chunk 6)
Assessment or monitoring of vitamin D status in patients with bone disease/osteoporosis, malabsorption, malnutrition, post‑bariatric surgery, altered calcium/phosphorus metabolism, transplant recipients, or on meds increasing vitamin D catabolism
Also indicated for symptomatic deficiency and very low baseline values.
Symptomatic vitamin D deficiency (e.g., hypocalcaemia or bone disease) — Repeat testing may be considered for monitoring after treatment
Manchester trust guidance supports repeat testing in symptomatic cases.
Malabsorption in a patient taking vitamin D — Repeat testing may be considered to assess adequacy of replacement
Per Manchester trust repeat-testing guidance.
Patients on oral anti-resorptive agents with low baseline vitamin D — Repeat testing may be considered
Repeat testing allowed per Manchester trust when baseline was low.
Testing Frequency and Retest Intervals
Coding and Definitions
Provider Actions, Documentation, and Billing
Prior authorization / coverage condition for 25‑OH testing
25-hydroxyvitamin D (25‑OH) serum testing meets coverage criteria only for individuals with an underlying disease/condition specifically associated with vitamin D deficiency or decreased bone density, for suspected hypervitaminosis D, or for individuals with documented vitamin D deficiency; testing is limited to no more than one test every six months.
- Coverage applies when indications listed in Note 1 are present (see policy Notes).
Retest timing requirement — minimum interval
Do not perform repeat 25(OH)D testing within three months of initiating vitamin D replacement; many guideline sources recommend waiting at least three months and preferably up to six months before retesting.
- RACGP: “Do not retest vitamin D levels within three months of the patient beginning to take vitamin D replacement.”
- Manchester NHS: “Repeat testing should not be done within three months of the initial test, and preferably not within six months.”
Therapy guidance — informational
Clinical guidance and public health recommendations (e.g., IOM) support routine dietary supplementation for many individuals, but this policy does not mandate or require specific therapy prior to testing; supplementation guidance is informational only.
- IOM and trial reviews recommend maintaining serum 25OHD between ~20–40 ng/mL; policy does not impose step‑therapy drug rules.
Empiric treatment alternative for asymptomatic high‑risk patients
Some guidance (Manchester NHS/Trust) recommends treating asymptomatic high‑risk individuals empirically with vitamin D supplementation without prior serum measurement; testing may be reserved for symptomatic individuals or those needing monitoring.
- Recommendation: “Asymptomatic individuals at high risk of Vitamin D deficiency should be treated without measurement of Vitamin D and should be advised on the need for maintenance dose Vitamin D supplementation.”
Testing may not be required prior to supplementation in asymptomatic high‑risk individuals
Guidance reiterates that asymptomatic high‑risk individuals may be treated with supplementation without measurement; therefore testing is not required in those cases unless clinical indications demand measurement or monitoring.
- Policy note: testing may be avoided in favor of empiric supplementation to reduce unnecessary testing workload.
Documentation and coding requirement for claims
Providers must submit accurate documentation of services performed and code claims according to industry standard coding/billing guidelines; failure to follow coding or billing guidance may result in claim denial or recoupment.
- Follow industry coding resources (CPT, HCPCS, ICD‑10, UB, CMS NCCI) when submitting claims.
- Inaccurate coding or documentation can lead to denial or claim recovery.
Recommended supporting documentation to justify testing
When ordering or requesting repeat testing, document supporting clinical data: prior abnormal 25‑OH results within 6 months, relevant biochemical indicators (calcium, phosphorus, alkaline phosphatase, PTH), and the clinical rationale (e.g., malabsorption, bone disease, medications) to justify the test.
- Include prior 25‑OH result if within 6 months and any abnormal biochemical indicators.
- Document clinical context such as malabsorption, anti‑resorptive therapy, or symptomatic deficiency.
Coding and assay regulatory documentation to include on claims
Include the specific CPT/HCPCS procedure code on claims (82306, 82652, or 0038U) and note the assay regulatory status when relevant (whether the laboratory test is an LDT and its CLIA high‑complexity classification).
- Identify the exact code for the analyte/method performed on the claim.
- If the lab uses an LDT, document that it is CLIA high‑complexity and any available validation details.
Denial risk for non‑medical‑necessity or miscoding
Claims for vitamin D testing may be denied if the service does not meet the policy's authorization and medical necessity criteria or if services are not coded according to standard coding guidelines.
- Tests without clinical indications listed in the policy or exceeding frequency limits risk denial.
- Incorrect coding or failure to document medical necessity may lead to denial or recoupment.
Unjustified test requests risk denial
A large retrospective study (32,363 tests) found a high proportion of vitamin D test requests were judged unjustified by medical criteria; requests lacking appropriate clinical indication are at risk for denial.
- Study finding: many test requests were unjustified by clinical and biochemical criteria, supporting stricter documentation of indications.
Repeat testing interval risk — potential denial for early repeats
Repeat 25‑OH testing performed within three months (and preferably within six months) of an initial test is not recommended by multiple guidance sources and may be considered unnecessary and subject to denial.
- RACGP and Manchester NHS guidance state retesting should not occur within three months of starting replacement and preferably not within six months.
Ordering Requirements
Ordering must be based on documented clinical indication and medical necessity
Order vitamin D testing only when there is documented clinical indication and medical necessity; appropriateness may be evaluated against the policy's listed indications.
Consider empiric supplementation for asymptomatic high‑risk individuals
Consider empiric vitamin D supplementation without measurement for asymptomatic high‑risk individuals per some NHS/Manchester guidance; otherwise, ordering should follow documented indications in the policy.
Document the clinical indication when ordering vitamin D tests
Follow clinical guidance when ordering tests and ensure documentation reflects the specific indication (for example, symptomatic deficiency, malabsorption, or monitoring during anti‑resorptive therapy).
Not Covered Services
Routine population screening of asymptomatic individuals and the use of serum 1,25-dihydroxyvitamin D to screen for deficiency are not covered. 1,25-dihydroxyvitamin D testing meets criteria only for evaluation of specific metabolic disorders described elsewhere in the policy.
Routine vitamin D screening/testing in asymptomatic members of the general population—including pregnant individuals and otherwise healthy children without bone disease—is not covered. Major guideline bodies advise against universal screening; testing should be reserved for documented clinical indications outlined in the policy.
Routine repeat vitamin D testing in the majority of patients is not covered. Repeat measurement should only be considered for the limited clinical situations enumerated in the policy, and testing within three months (preferably within six months) of the prior result is excluded.
Definitions
Background
25-hydroxyvitamin D (25OHD) is the predominant and most stable circulating form of vitamin D and is the preferred analyte to evaluate vitamin D status. The active hormone, 1,25-dihydroxyvitamin D, has a much shorter half-life and is used selectively for evaluating defects in vitamin D metabolism rather than routine status assessment. Vitamin D deficiency is commonly defined as serum 25OHD <20 ng/mL and is associated with rickets, osteomalacia, osteoporosis, and increased fracture risk; testing should be targeted to patients with relevant risk factors or clinical indications.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.